[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 5, 2005

High-Dose Statins in Acute Coronary Syndromes—Reply

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(1):36-39. doi:10.1001/jama.293.1.39-a

In Reply: Dr Mitchel asserts that the muscle toxicity observed during the failed development of the 160-mg dose of simvastatin is not relevant to the interpretation of the A to Z trial. I strongly disagree. The margin of safety of a drug is always relevant. This is particularly true for drugs such as simvastatin, which is metabolized by cytochrome P450 3A4. Coadministration with 3A4 inhibitors and other agents, including erythromycin, amiodarone, verapamil, or antifungals, can significantly elevate simvastatin blood levels.1 In this way, the blood levels achieved with the 80-mg dose of simvastatin used in the A to Z trial can reach the toxic levels that led to termination of the development of the 160-mg dose of simvastatin.

First Page Preview View Large
First page PDF preview
First page PDF preview
×